Daily non-political popular news in brief.
Drug that mimics 'good' cholesterol has mixed effect on coronary atherosclerosis
03-26-2007 · EurekAlert!The results of a study presented today at the American College of Cardiology’s 56th Annual Scientific Session showed that CSL-111, a drug that mimics HDL, did not significantly reduce plaque in coronary arteries in patients with a recent episode of ACS. However, patients taking the drug showed improvement in two indexes that assess changes in the blood vessels.
Read more »
Keywords: drug, mimics, good, cholesterol, mixed, effect, coronary, atherosclerosis, mimic, atherosclerosi
« Previous | Next »
Similar news on "Drug that mimics 'good' cholesterol has mixed effect on coronary atherosclerosis":
- Novel therapy for lipid disorders shows mixed results in early clinical trials
03-25-2007 · EurekAlert!
Preliminary research suggests that use of a novel, potent drug to treat cholesterol disorders decreases triglycerides and increases HDL-C, the "good" cholesterol, but also raises some safety concerns, according to a study in the March 28 issue of JAMA. The study is being released early to coincide with its presentation at the American College of Cardiology's annual conference.
Similar news · Read more »
- Statin therapy associated with regression of coronary atherosclerosis with key lipid level changes
02-06-2007 · EurekAlert!
An analysis of data from four clinical trials suggests that statin therapy is associated with regression of coronary atherosclerosis when low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) is substantially reduced and high-density lipoprotein cholesterol (HDL-C or "good" cholesterol) is increased, but it remains to be determined whether this degree of atherosclerosis regression will translate to meaningful reductions in cardiovascular events, according to a study published in the Feb. 7 issue of JAMA.
Similar news · Read more »
- Despite significantly raising HDL, torcetrapib failed to slow the progression of coronary plaques
03-26-2007 · EurekAlert!
Investigators reported today at the American College of Cardiology's 56th Annual Scientific Session that torcetrapib, a drug that substantially raises high-density lipoprotein cholesterol or HDL (the "good" cholesterol), did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe (IVUS).
Similar news · Read more »
- Combination HDL/LDL therapy has no effect on plaque build-up
03-26-2007 · EurekAlert!
Two RADIANCE studies presented today at the American College of Cardiology's 56th Annual Scientific Session assessed the effects of adding torcetrapib to atorvastatin among patients to improve their cholesterol levels. Although the ILLUMINATE study and other trials involving torcetrapib were recently stopped because of safety concerns, the effect of the drug on carotid intima-media thickness (CIMT) may provide useful information on whether it slows the progression of atherosclerosis.
Similar news · Read more »
- Stress triggers relapse in meth abuse, OHSU study finds
10-18-2006 · EurekAlert!
Oregon Health & Science University research showing stress triggers relapse of methamphetamine abuse in mice could be a step toward developing a drug to curb this frustrating obstacle to recovery. Results of the study not only validate earlier studies on the effects of stress on drug relapse in humans, they also show a compound researchers used to mimic metabolic changes that occur during stress creates a useful model for studying this effect in the laboratory.
Similar news · Read more »
- Statins reduce loss of function, keeping old lungs young - even in smokers
10-12-2007 · EurekAlert!
Statins are known to be good for lowering cholesterol and maybe even fighting dementia, and now they have another reported benefit: they appear to slow decline in lung function in the elderly -- even in those who smoke. According to researchers in Boston, it may be statins' anti-inflammatory and antioxidant properties that help achieve this effect.
Similar news · Read more »
- Statin therapy slows progression of arterial thickening; halts but does not reverse atherosclerosis
03-25-2007 · EurekAlert!
Among low-risk middle-aged people with subclinical atherosclerosis, the cholesterol-lowering drug rosuvastatin reduces the rate of progression of arterial thickening and stops but does not reverse atherosclerotic disease, according to a study in the March 28 issue of JAMA. The study is being released early to coincide with its presentation at the American College of Cardiology's annual conference.
Similar news · Read more »
- Crestor effective at halting early atherosclerosis
03-25-2007 · EurekAlert!
An international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting early changes in the blood vessels that can lead to atherosclerosis.
Similar news · Read more »
- JCI table of contents: Sept. 6, 2007
09-06-2007 · EurekAlert!
This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published online, Sept. 6, 2007, in the JCI, including: Hunger hormone fights aging in the thymus; Drug's potential adverse side effect explained; To kill or not kill that is the questions for IFN-alpha; When does being obese not lead to diabetes" When mice lack osteopontin; Understanding why infection with HIV-2 is not as bad as HIV-1; and others.
Similar news · Read more »
- Negativity is contagious, study finds
10-04-2007 · EurekAlert!
Though we may not care to admit it, what other people think about something can affect what we think about it. This is how critics become influential and why our parents' opinions about our life choices continue to matter, long after we've moved out. But what kind of opinions have the most effect? An important new study in the Journal of Consumer Research reveals that negative opinions cause the greatest attitude shifts, not just from good to bad, but also from bad to worse.
Similar news · Read more »
